BioSpace News Archive

Accuray Incorporated (NASDAQ: ARAY) announced today data from a prospective study which showed that at five years, stereotactic body radiation therapy (SBRT) administered with the CyberKnife® System provided excellent disease control with low rates of toxicity in men with locally recurrent prostate cancer after previous treatment with radiation therapy.

Aclaris Therapeutics, Inc., a physician-led biopharmaceutical company focused on immuno-inflammatory diseases, announced the appointment of Vincent Milano to its board of directors, effective January 7, 2020.

Three Products Advancing in the Clinic with Additional Pipeline Growth to Come from Internal Research and Partnerships

AbbVie announced the creation of a new global business, Allergan Aesthetics, an AbbVie company, and the proposed leadership team for the combined company, effective upon the expected first-quarter 2020 close of the Allergan acquisition.

Transcenta Holding Limited (“Transcenta”), a global biotherapeutics company with fully-integrated capabilities in discovery, R&D, and manufacturing of antibody-based therapeutics, announces today that it has sealed a 100 million USD series B+ round.

Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company with a broad pipeline of biotherapeutics in development, announced today the administration of the first dose of INBRX-106 in a Phase 1 dose-escalation clinical study.

Knight Therapeutics Inc., a pan-American specialty pharmaceutical company and Debiopharm, a Swiss-based, global biopharmaceutical company, announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® in Canada.

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced independent centrally reviewed top-line data for pralsetinib in patients with RET fusion-positive non-small cell lung cancer (NSCLC).

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced the appointment of Gayle Crowell to its board of directors as an independent director.

KIYATEC, Inc. announced that it has secured an investment from life sciences venture investment company Esperante.